AdBio partners

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with additional research facilities in Nice. Founded in 2019, DiogenX specializes in developing pancreatic beta-cell modulators aimed at treating Type 1 and Type 2 diabetes. The company's primary focus is on creating a candidate molecule that regenerates pancreatic insulin-producing cells in diabetic patients, which has the potential to improve both quality of life and survival rates. This innovative approach to therapy was initially discovered in the laboratory of Dr. Patrick Collombat at Inserm, CNRS, and Nice University, positioning DiogenX as a pioneer in beta-cell regeneration for diabetes treatment.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Integra Therapeutics is focused on advancing gene editing technologies to address various diseases. The company is developing innovative gene writing tools that aim to enhance the effectiveness of gene therapy. By combining the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in the field of gene editing. This approach allows scientists to introduce DNA into a genome using sequence-specific DNA binding proteins, thereby facilitating the development of targeted gene therapies that meet the specific needs of patients.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in the resolution of inflammation. The company develops treatments based on monoclonal antibodies by treating human mucosal inflammatory diseases by inhibiting a target that could be implied in the early inflammatory process and the recruitment of innate immunity cells, enabling healthcare providers to cure their patients.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with additional research facilities in Nice. Founded in 2019, DiogenX specializes in developing pancreatic beta-cell modulators aimed at treating Type 1 and Type 2 diabetes. The company's primary focus is on creating a candidate molecule that regenerates pancreatic insulin-producing cells in diabetic patients, which has the potential to improve both quality of life and survival rates. This innovative approach to therapy was initially discovered in the laboratory of Dr. Patrick Collombat at Inserm, CNRS, and Nice University, positioning DiogenX as a pioneer in beta-cell regeneration for diabetes treatment.

Wellium SAS, established in 2016 and headquartered in Levallois-Perret, France, specializes in digital transformation tools for the medical sector. The company provides teleconsultation solutions aimed at improving healthcare access and efficiency. Its flagship products include Feelae, an application that enables patients to receive medical care remotely, addressing issues such as medical desertification and overcrowding in emergency services, and Leah, a teleconsultation platform designed specifically for healthcare professionals to consult with their patients online. Through these innovations, Wellium aims to enhance the overall healthcare experience for both patients and doctors.

Alderaan Biotechnology is a Biotechnology company develops antibodies targeting new and original targets in immuno-oncology, expressed by NK cells in particular.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients with Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two primary drug discovery programs aimed at identifying selective HDAC6 inhibitors and GABABR1a agonists. These compounds are designed to offer neuroprotection against nerve degeneration and to promote the repair of peripheral myelin. Through its research and development efforts, Augustine Therapeutics aims to enhance the quality of life for patients afflicted with these challenging neurological conditions.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company specializes in a unique peptide that helps maintain a cluster of truncated CD31 molecules at the cell membrane, which allows for the modulation of overactive immune responses without complete blockade. By providing this innovative approach, Tridek-One enables medical companies to offer improved treatment options for patients, enhancing their quality of life.

Yukin Therapeutics is a French biotechnology company. The company focuses on the development of new therapeutic molecules, entitled kinase inhibitors, specifically targeting a protein involved in the development of several types of cancer: the NIK protein (NF-κB inducing kinase). Yukin Therapeutics led studies that demonstrated proof of concept in animal models and is now actively seeking to identify a first drug candidate to launch a clinical trial in oncology.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Alderaan Biotechnology is a Biotechnology company develops antibodies targeting new and original targets in immuno-oncology, expressed by NK cells in particular.